Program
Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028
Its studies are mostly in Prostatic Neoplasms, led by Arsenal Biosciences.
Furthest: phase 2, since Dec 10, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arsenal Biosciences | 10 open or running | phase 2since Dec 10, 2025 | Dec 10, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 10, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07285694 · 3 enrolled · United States
TargetBeta
“A preparation of autologous T-lymphocytes that have been modified to encode a genetic circuit consisting of a priming receptor that induces the expression of a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) upon binding to an”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07285694Prostatic Neoplasms · United States | 2 | Terminated | Oct 19, 2026 | 3 |
How it is read
Names in the registry
- “AB-3028”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.